Ali, Abdullah Mahmood
BenMohamed, Fatima
Decina, Alessandra
Mukherjee, Sanjay
Levi, Shelley
Garrido Castillo, Laura Nalleli
Bréchot, Davide
Jurcic, Joseph
Raza, Azra http://orcid.org/0000-0002-9734-5210
Paterlini Bréchot, Patrizia http://orcid.org/0000-0001-7981-6325
Funding for this research was provided by:
Rarecells Inc.
Article History
Received: 18 May 2023
Accepted: 20 May 2023
First Online: 14 June 2023
Declarations
:
: AR received funding from Rarecells. AMA and AR are co-inventors on a pending patent application describing the targeting of giant and or hybrid cells. The pending patent application is licensed to TFC Therapeutics. AMA and AR have equity interest and are consultants in TFC Therapeutics. PPB is inventor on a pending patent application describing companion diagnostic biomarkers on circulating cancer giant cells and of ISET technology; she is President of Rarecells Inc and Rarecells Diagnostics with equity interests in Rarecells. FBM, AD, LNGC, DB are employees of Rarecells Diagnostics. All other authors declare no competing interests.
: This study is approved by the institutional review board of Columbia University Irving Medical Center under IRB protocol AAAR7591 and is performed in accordance with the declaration of Helsinki.